Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
Public ClinicalTrials.gov record NCT00002070. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine whether co-administration of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) improves tolerance to ganciclovir in patients previously intolerant because of neutropenia defined as an absolute neutrophil count less than 500 cells/mm3. To assess if improved tolerance of ganciclovir is associated with a favorable outcome as defined by a delayed time to progression of retinitis; to confirm the safety and co-administration of ganciclovir and GM-CSF; to assess the changes in the expression of HIV p24 antigen in the serum and number of T4+ lymphocytes in the blood of patients receiving ganciclovir with or without GM-CSF.
Study identification
- NCT ID
- NCT00002070
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jun 23, 2005
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC School of Medicine / Norris Cancer Hosp | Los Angeles | California | 90033 | — |
| UCLA CARE Ctr | Los Angeles | California | 90095 | — |
| Children's Hosp of San Francisco | San Francisco | California | 94118 | — |
| Pacific Presbyterian | San Francisco | California | 94118 | — |
| Gottlieb Med Group | Sherman Oaks | California | 91403 | — |
| AIDS Research Consortium of Atlanta | Atlanta | Georgia | 30308 | — |
| Rush Presbyterian - Saint Luke's Med Ctr / Rush Med Coll | Chicago | Illinois | 60612 | — |
| Cabrini Med Ctr | New York | New York | 10003 | — |
| Dr Douglas Dieterich | New York | New York | 10016 | — |
| Saint Luke's - Roosevelt Hosp Ctr | New York | New York | 10025 | — |
| Univ of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Univ of Texas Southwestern Med Ctr of Dallas | Dallas | Texas | 75235 | — |
| Methodist Hosp | Houston | Texas | 77030 | — |
| Infectious Disease Physicians Inc | Annandale | Virginia | 22203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00002070, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2005 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00002070 live on ClinicalTrials.gov.